Tgf-beta 1 expression as a biomarker of poor prognosis in prostate cancer
Carregando...
Citações na Scopus
68
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.66, n.7, p.1143-1147, 2011
Resumo
OBJECTIVE: To evaluate the correlation between transforming growth factor beta (TGF-beta 1) expression and prognosis in prostate cancer. PATIENTS AND METHODS: TGF-beta 1 expression levels were analyzed using the quantitative real-time polymerase chain reaction to amplify RNA that had been isolated from fresh-frozen malignant and benign tissue specimens collected from 89 patients who had clinically localized prostate cancer and had been treated with radical prostatectomy. The control group consisted of 11 patients with benign prostate hyperplasia. The expression levels of TGF-beta 1 were compared between the groups in terms of Gleason scores, pathological staging, and prostate-specific antigen serum levels. RESULTS: In the majority of the tumor samples, TGF-beta 1 was underexpressed 67.0% of PCa patients. The same expression pattern was identified in benign tissues of patients with prostate cancer. Although most cases exhibited underexpression of TGF-beta 1, a higher expression level was found in patients with Gleason scores >= 7 when compared to patients with Gleason scores <7 (p = 0.002). Among the 26 cases of TGF-beta 1 overexpression, 92.3% had poor prognostic features. CONCLUSIONS: TGF-beta 1 was underexpressed in prostate cancers; however, higher expression was observed in tumors with higher Gleason scores, which suggests that TGF-beta 1 expression may be a useful prognostic marker for prostate cancer. Further studies of clinical specimens are needed to clarify the role of TGF-beta 1 in prostate carcinogenesis.
Palavras-chave
Prostate cancer, Prognosis, Molecular markers, TGF-beta
Referências
- Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
- YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731
- DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0
- ALEXANDROW MG, 1995, CANCER RES, V55, P1452
- Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807
- Lee C, 1999, PROSTATE, V39, P285
- Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137
- WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
- Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445
- Barrack ER, 1997, PROSTATE, V31, P61
- Shariat SF, 2004, CLIN CANCER RES, V10, P1992, DOI 10.1158/1078-0432.CCR-0768-03
- SUTKOWSKI DM, 1992, PROSTATE, V21, P133, DOI 10.1002/pros.2990210206
- Shariat SF, 2004, UROLOGY, V63, P1191, DOI 10.1016/j.urology.2003.12.015
- Soulitzis N, 2006, INT J ONCOL, V29, P305
- Edwards DR, 1996, EXP GERONTOL, V31, P207, DOI 10.1016/0531-5565(95)02010-1
- ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO;2-0
- Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118
- FARIA PC, 2007, CANC INVESTIGATION, V725, P726
- FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156
- MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1
- MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963
- MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x
- WILDING G, 1991, CANCER SURV, V11, P147